Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5402
Abstract: Introduction: In Italy, Brentuximab vedotin (Bv) with AVD (adriamycin, vinblastine, dacarbazine) received approval for the first-line treatment of stage IV classical Hodgkin lymphoma (cHL) in September 2021, with no upper age restriction. Considering the upcoming… read more here.
Keywords: age; avd abvd; group; age years ... See more keywords